or Try an Advanced Search...

    Technical Analysis for TH - Theratechnologies Inc.

    Grade Last Price % Change Price Change
    C 2.000 0.00% 0.000
    TH closed unchanged on Friday, July 26, 2024, on 89 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical TH trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    200 DMA Support Bullish 0.00%
    Gapped Down Weakness 0.00%
    20 DMA Resistance Bearish 0.00%
    200 DMA Support Bullish 0.00%
    Fell Below 20 DMA Bearish -0.50%
    MACD Bearish Signal Line Cross Bearish -0.50%
    200 DMA Support Bullish -0.50%
    Outside Day Range Expansion -0.50%
    Gapped Up Strength -0.50%
    Older End-of-Day Signals for TH ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 11 hours ago
    Rose Above 20 DMA about 11 hours ago
    200 DMA Support about 11 hours ago
    Up 2% about 11 hours ago
    Up 1% about 11 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TH Chart by TradingView
    Basic chart:

    Profile

    Theratechnologies Inc. Description

    Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Pharma Pharmaceutical Drug Medical Specialties IPO Organ Systems Hiv Immunology Infection Rift Antivirals

    Is TH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 16 Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
    Jul 16 Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
    Jul 10 HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
    Jul 10 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
    Jun 26 Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
    Jun 13 Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability
    Jun 5 Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
    May 23 Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate
    May 23 Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
    May 9 Theratechnologies Reports on its Annual Meeting of Shareholders
    See more TH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.45
    52 Week Low 0.75
    Average Volume 17,150
    200-Day Moving Average 1.986
    50-Day Moving Average 1.862
    20-Day Moving Average 2.010
    10-Day Moving Average 2.082
    Average True Range 0.119
    RSI (14) 51.69
    ADX 36.33
    +DI 26.277
    -DI 16.267
    Chandelier Exit (Long, 3 ATRs) 1.922
    Chandelier Exit (Short, 3 ATRs) 2.088
    Upper Bollinger Bands 2.201
    Lower Bollinger Band 1.819
    Percent B (%b) 0.47
    BandWidth 19.045
    MACD Line 0.055
    MACD Signal Line 0.069
    MACD Histogram -0.0134
    Fundamentals Value
    Market Cap 154.03 Million
    Num Shares 77 Million
    EPS -0.09
    Price-to-Earnings (P/E) Ratio -22.47
    Price-to-Sales 2.87
    Price-to-Book 21.32
    PEG Ratio -199.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.150
    Resistance 3 (R3) 2.150 2.100 2.125
    Resistance 2 (R2) 2.100 2.062 2.100 2.117
    Resistance 1 (R1) 2.050 2.038 2.075 2.050 2.108
    Pivot Point 2.000 2.000 2.013 2.000 2.000
    Support 1 (S1) 1.950 1.962 1.975 1.950 1.892
    Support 2 (S2) 1.900 1.938 1.900 1.883
    Support 3 (S3) 1.850 1.900 1.875
    Support 4 (S4) 1.850